Thought Leadership

The Shift Toward Globalization in Medical Information: How Radiofilum Pharmaceutical is Helping Shape the Future in Japan

Radiofilum Pharmaceutical Staff — Thu, 16 Oct 2025 11:00:00 GMT

Over the past decade, the pharmaceutical industry has moved steadily toward the globalization of Medical Information (MI) services. Standard Operating Procedures (SOPs), harmonized processes, and unified technology platforms have transformed how companies operate. Now, this evolution is extending to contact center operations — an area where consistency, compliance, and responsiveness are critical.

Medical Information in the Netherlands: Safeguarding Compliance and Patient Confidence

Radiofilum Pharmaceutical Staff — Thu, 02 Oct 2025 11:00:01 GMT

Access to trustworthy pharmaceutical information is essential for patient safety and informed decision-making. In the Netherlands, medical information (MI) services are central to this goal, providing healthcare professionals, patients, and caregivers with accurate, non-promotional product knowledge.

Tips for Preparing Successful FDA 510(k) Submissions

Radiofilum Pharmaceutical Staff — Tue, 30 Sep 2025 20:34:45 GMT

Securing FDA clearance through the 510(k) process is a critical milestone for many medical device manufacturers seeking market entry in the US. While the pathway is well-defined, many submissions face delays, or worse, denial, due to incomplete documentation, misaligned strategies, or preventable errors. Careful preparation can make the difference between a smooth clearance process versus one that incurs a prolonged timeline and various setbacks.

FDA’s Crackdown on Drug Advertising: Key Lessons from 60 Compliance Letters in 2025

Jason Cober — Fri, 26 Sep 2025 17:10:19 GMT

On September 25, 2025, FDA posted an additional 11 Untitled Letters from the cohort of letters issued on September 9, 2025, bringing the total number of compliance letters directed toward prescription drug and biologic promotional communications to 60. For reference, this is a massive increase compared to the 5 letters (3 untitled letters and 2 warning letters) issued from January 1 – September 8, 2025.

How to Select the "Right" CMO Partner

Radiofilum Pharmaceutical Staff — Thu, 18 Sep 2025 11:00:00 GMT

There are many ways in which you can evaluate a Contract Manufacturing Organization (CMO) to identify the best fit for your company's needs.

Decoding FDA’s Recent Advertising Enforcement Actions

Jason Cober — Wed, 17 Sep 2025 17:15:00 GMT

The Agency’s Advertising Enforcement Letters Reveal Shifting Regulatory Priorities

On Tuesday, September 16, 2025, FDA posted 40 Untitled Letters and 8 Warning Letters directed at prescription drug and biologic Sponsors’ promotional communications. This is the first round of letters following FDA’s sweeping marketing and advertising enforcement announcement regarding its crackdown on deceptive drug advertising, and this blitz provides some clarity on the Agency’s regulatory direction and priorities.

Here’s what we have learned:

FDA Launches Crackdown on Deceptive Drug Advertising

Radiofilum Pharmaceutical Staff — Wed, 10 Sep 2025 19:33:03 GMT

On September 9, 2025, the US Department of Health and Human Services (HHS) and FDA unveiled a sweeping effort to clamp down on misleading direct-to-consumer (DTC) pharmaceutical advertising. The Agency announced it would:

Creating an Effective Global Audit Strategy for Medical Device and Diagnostics

Ben Frey — Wed, 10 Sep 2025 11:00:00 GMT

The Crossroads of Global Compliance

For medical device and diagnostic companies operating in today’s global marketplace, success depends on more than just innovative products — it hinges on a consistent, compliant, and inspection-ready quality system across every region of operation. But with regulatory frameworks evolving across the U.S., Europe, and Asia, maintaining a cohesive audit strategy can feel like navigating a maze.

FDA to Release CRLs in Real Time: What Does This Mean for Drug Developers?

Radiofilum Pharmaceutical Staff — Tue, 09 Sep 2025 16:00:00 GMT

On September 4, 2025, FDA announced a sweeping policy change: the real-time release of Complete Response Letters (CRLs); a continuation of FDA's July 10, 2025 publication of previously undisclosed letters. This initiative is part of FDA's push toward greater transparency and accountability, representing a cultural shift in how the Agency communicates with the pharmaceutical industry, investors, and the public.

For decades, CRLs were considered private communications between the FDA and a drug Sponsor and Sponsors were not required to disclose specific deficiencies from CRLs. With this new policy, those days are over.

Transparency Requirements and the Requirement for Document Redaction

Radiofilum Pharmaceutical Staff — Tue, 09 Sep 2025 13:42:04 GMT

In an era of increasing scrutiny and demand for transparency in clinical research, the European Union (EU) has taken significant strides to enhance public access to clinical trial data and ensure the integrity of the research process. The EU Clinical Trial Regulation (CTR) (No. 536/2014) is central to these efforts, establishing rigorous transparency requirements that aim to foster public trust, safeguard patient safety, and improve the overall efficiency of clinical trials.